comparemela.com
Home
Live Updates
Umor Gastrointestinal Stromal - Breaking News
Pages:
Umor Gastrointestinal Stromal News Today : Breaking News, Live Updates & Top Stories | Vimarsana
FDA Approves New Indication for Avapritinib
Avapritinib (AYVAKIT) is now approved to treat adults with indolent systemic mastocytosis.
Judith kain emmel
Blueprint medicines corp
Drug administration
Mast cell disease society
Kain emmel
Lysosomal storage disease
Systemic mastocytosis
Peripheral edema
Bone marrow
Platelet growth factor
Platelet derived growth factor
Tyrosine kinase inhibitor
Biologic therapy
Gastrointestinal stromal tumor
Umor gastrointestinal stromal
Hematologic disorders
Where Does Ripretinib Fit Into Treatment for GIST?
The relative newcomer to the field, ripretinib, was compared to standard second-line treatment with sunitinib in patients with advanced gastrointestinal stromal tumors.
New york
United states
Columbia university
West german
Sebastian bauer
Gary schwartz
Daiichi sankyo
Nanobiotix incyte
Drug administration
Boehringer ingelheim
Deciphera pharmaceuticals
German cancer centre
Clinical oncology
West german cancer centre
Blueprint medicines
Adcendo aps
Ripretinib Safer Than Sunitinib for GIST, Fails to Improve PFS
The findings suggest that ripretinib (Qinlock) provides a similar PFS benefit but may come with notably better tolerability compared with sunitinib.
United states
Dana farber cancer institute
Michaelc heinrich
American society of clinical oncology plenary series
Theseus pharmaceuticals
Oregon health science university
Harvard medical school
Deciphera pharmaceuticals
Sarcoma center at dana farber cancer institute
Oregon health
Science university
American society
Clinical oncology plenary
Sarcoma center
Harvard medical
Blueprint medicines
vimarsana © 2020. All Rights Reserved.